Our medicines Our stories Investors

Skip to main content

Contact us Careers

Americas

Argentina

Brazil

Canada

Chile

Colombia

Mexico

Peru

United States

Asia Pacific

Australia

China

Simplified Chinese

India

Japan

Korea

Korean

New Zealand

Singapore

Taiwan

Traditional Chinese

Thailand

Europe

Austria

German

Belgium

English Dutch French

Czech Republic

Czech

Denmark

Danish

Finland

France

French

Germany

German

Greece

Greek

Hungary

Ireland

Italy

Luxembourg

Netherlands

Norway

Poland

Polish

Portugal

Romania

Spain

Sweden

Switzerland

United Kingdom

Middle East

Israel

Hebrew

Saudi Arabia

Turkey

United Arab Emirates

Other

Other Markets

Distributor Markets

bmsUScqPageLucene

Medicines > Careers > Press Releases > Medical Information >

Our Medicines

Patients & caregivers

Our medicines

Get help paying for your medicines

Patient resources

Risk evaluation and mitigation strategies (REMS)

QUICK LINKS

Immunology patient resources

Our position on generic drugs

Our position on drug pricing

Psoriasis around the world

Healthcare providers

Learn about pre-approval access

Learn about post study drug access

340B practice fact sheet

QUICK LINKS

U.S. medical information

Clinical trials

Pre-approval access request system

Post study drug access request system

Researchers

Areas of focus

In the pipeline

R&D expert voices

Our efforts in STEM

Clinical trials & research

Independent research

The Thomas O. Daniel research incubator and collaboration center

QUICK LINKS

Perspectives from our head of research

Research publications

Disclosure commitment

Investigator sponsored research portal

Areas of interest & competitive research grants

Compound & technology requests

Data sharing request process

Translational medicine

Investors

Stock information

Financial reporting

Analyst coverage

Events and presentations

Shareholder services

Acquisition-related information for Celgene shareholders

Investor contacts

QUICK LINKS

Annual report 2023

Dividend history

Stock split history

Investment return calculator

SEC filings

Quarterly results

Product sales summary

Annual reports archive

Annual meeting of shareholders

Business development

Our partnerships

Why partner with us

Areas of interest

Business development leadership team

Begin a discussion

Global alliances leadership team

Early innovation at BMS

QUICK LINKS

Download business development brochure

"Golden Ticket" contests

News

Press releases

Our stories

Medical meetings

Media library

Media contacts

QUICK LINKS

Scientific media resources

Disease state infographics

Corporate publications

About us

Our company

Leadership

Global Inclusion & Diversity

Responsibility

Sustainability at Bristol Myers Squibb

Contact us

QUICK LINKS

Global Patient Week

Survivorship Today

Our technologies

History timeline

Worldwide locations

The Bristol Myers Squibb Foundation

People & Business Resource groups

Our commitment to global inclusion and diversity

Position on key issues

Our stories / News & Perspectives / Bristol Myers Squibb Receives an FDA Approval

Lung Cancer

Bristol Myers Squibb Receives an FDA Approval

Main navigation

Home
Patients & caregivers
Healthcare providers
Researchers
Investors
News
About us

Resources

Our medicines
Legal notice
Privacy notice
Trademarks
Forward-looking statement
UK-CA slavery and human trafficking statement (PDF)

Follow us

Careers
Our stories
Contact us
Worldwide locations

September 15, 2020

© 2024 Bristol-Myers Squibb Company